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osting by EAbstract Migraine is one of the common causes of severe and recurring headache. It may be difﬁ-
cult to manage in primary care settings, where it is under diagnosed and medically treated. Migraine
can occur in children as well as in adults and it is three times more common in women than in men.
Migraine in children is different from adults in various ways. Migraine management depends on the
various factors like duration and severity of pain, associated symptoms, degree of disability, and ini-
tial response to treatment. The therapy of children and adolescents with migraines includes treatment
modalities for acute attacks, prophylactic medications when the attacks are frequent, and biobeha-
vioural modes of treatment to aid long-term management of the disorder. The long lasting outcome
of childhood headaches and progression into adult headaches remains largely unknown. However, it
has been suggested that adult migraine may represent a progressive disorder. In children, the pro-
gressive nature is uncertain and further investigations into longitudinal outcome and phenotypic
changes in childhood headaches have yet to be recognized. Even though paediatric and adult
migraines seem to be slightly different from one another, but not enough to categorize either as sole.
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Migraine is an intermittent, often unbearable headache related
health problem that causes signiﬁcant impairment to the pa-
tient’s quality of life. Migraine in children can present con-
trarily from that is seen in adults. Certain variants of
migraine are distinctive to children and but hardly ever, occur
in adults. Neurological symptoms (Aura) may be more conspic-
uous than the headache and apart from these, there may be
other nonheadache symptoms also (Stewart et al., 1991). Vari-
ous recognized childhood syndromes that are assumed to be re-
lated to migraine include benign paroxysmal vertigo of
childhood, cyclic vomiting syndrome, abdominal migraine
and acute confusional migraine (Welch, 2003). Benign paroxys-
mal vertigo of childhood is usually seen in toddlers, acute con-
fusional migraine exhibits in early school years, and hemiplegic
migraine presents in early childhood. While basilar migraine is
present more in adolescents, females and opthalmoplegic mi-
graine is seen later. Variant migraine incidents may be sover-
eign of actual headache. Other symptoms may prevail and be
signiﬁcantly more bothersome (Brandes, 2008).
Migraine ache is not identical in all sufferers, but it can gen-
erally be illustrious from other types of headache. Typically the
symptoms in adults and children are unlike. Usual symptoms in
adults include extreme pain on one or both sides of the head,
throbbing in nature, pain in the eye, jaw, face or neck, photo-
phobia and phonophobia, nausea and vomiting and symptoms
worsen with even minor exertion. Usually migraines episodes
typically last 4–72 h. Sometimes tension headaches, cluster
headaches and the headache of subarachnoid haemorrhage
are mistaken for migraine. The ﬁrst, migraine sufferers can be
ruled out subarachnoid haemorrhage by a computerized tomog-
raphy (CT) scan and spinal tap.Usuallymigraines in a single pa-
tient resemble each other and the patient identiﬁes that this is his
or her typical headache. In contrast to the adult migraines, chil-
dren have a tendency to occur all over the head instead of just
one side, and tend to be shorter period than migraines in adults.
Occasionally children have the symptoms that escort a migraine
which are light sensitive, nausea, and vomiting without any
headache. This type is called an abdominal migraine, and is usu-
ally be hard to diagnose (Pakalnis, 2001).1.1. Epidemiology
The World Health Organization positions migraines as the
19th leading reason of disability worldwide. Globally mi-
graines affect around 10% of people. Headache, and more par-
ticularly migraine, is a frequent health problem in children as
well as adolescents. Various estimates show that headaches oc-
cur in up to 3/4th of adolescents and 1/4th of younger child.
The greatest impact on a child and parent is from migraine,
which occurs in up to 10.6% of children between the ages of
5 and 15 years, and 28% in children aged between 15 and
19 years. So this prevalence ranks headache and migraine in
the top ﬁve health problems of childhood. The prevalence of
migraine differs considerably by age and gender (Burton et
al., 2009). Below the age of 12 years, migraine is more common
in boys than in girls, but prevalence increases more rapidly in
girls after puberty. Above the age 12, females are two to three
times more likely to have migraine than males to suffer from
migraine. Difference between genders in migraine prevalence
has been linked to menstruation, but these differences persist
beyond menopause. Prevalence is highest in both men and wo-
men between the ages of 25 and 45 years. The usual age of on-
set is 12 to 17 years of age for females and 5 to 11 years for
males with incidence of migraine with aura cresting earlier in
this range for both. In the American Migraine Study II, 92%
of women and 89% of men with migraine reported some head-
ache-related disability, and 53% were severely disabled or
needed bed rest during an attack (Buse et al., 2009). Number
of neurologic and psychiatric disorders, including epilepsy,
stroke, major depression and anxiety disorder, show increased
co-morbidity with migraine. Whether this relationship is cau-
sal or representative of a common pathophysiologic mecha-
nism is unknown. The economic burden of migraine is
signiﬁcant; yet, the direct medical costs associated with mi-
graine treatment are more surpassed by the indirect costs that
result from work-related disability (Freitag, 2007).
The outstanding work of Bile on childhood headache and
migraine is one of the earliest well conducted population based
study. Bille studied the incidence of headaches in 9000 school-
aged children in Sweden in 1962 (Bille, 1962). In this investiga-
tion, he reported that by age six years, 39% of children had
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to 70% by age 15 years. Other studies have reported resem-
bling drifts with an incidence as high as 82%. A study con-
ducted in Taiwan showed that approximately 85% of
children aged 13–15 has had headaches (Lu et al., 2000). Other
studies showed that up to 51% of children aged seven years
and 57–82% of adolescents aged 15 years report recurrent
headaches. The prevalence of migraines in the adolescent pop-
ulation has been estimated worldwide to be around 4–10%
(Fendrich et al., 2007). Study conducted by Anttila et al con-
cluded the incidence rates of migraine and frequent headache
in seven year old Finnish schoolchildren increased from 1974
to 2002 (Anttila et al., 2006). Sillanpaa also reported a 5.7%
migraine prevalence rate in Finnish school children and sug-
gested that overall rate may be increased substantially over
the past two decades (Sillanpaa et al., 1991).
1.2. Migraine variants in children
In abdominal migraine, the child may exhibit symptoms of epi-
sodic abdominal pain, nausea and vomiting. Headache may be
minimal or absent. Symptoms are relieved by sleep, antiemetic
and antimigraine therapy. Cyclic vomiting syndrome in child-
hoodmay be a severe variant of abdominal migraine. Diagnosis
is difﬁcult to make during the ﬁrst episode, but must be consid-
ered whenever a child complains of abdominal pain. Trauma
triggeredmigraine, acute minor head trauma can also trigger at-
tacks ofmigraine in children. Confusional migraine, this variant
is less commonly seen in adults. Occasionally a child, whose mi-
graine episode begins in the pre-pubertal years continues into
adolescence. The child has a period of confusion and disorienta-
tion, with or without agitation followed by vomiting which is re-
lieved by sleep (Ravishankar, 2004). Headache may not be
prominent or may be elicited only retrospectively. Diagnosis
during the ﬁrst attacks is difﬁcult and it can be made only after
the episode has resolved fully. Differential diagnosis of a single
episode includes all types of encephalopathy, ingestion of toxic
substances, intoxication or an unobserved seizure with postictal
agitation. Next type is BasilarMigraine, which is quite common
in adolescent girls. The patient experiences an aura followed by
dizziness, vertigo, syncope, inner ear disease and posterior fossa
tumours. Hemiplegicmigraine presents with hemiplegia or hem-
iparesis, with or without a speech or language disturbance,
whichmay take minutes to hours to clear. Headachemay be less
drastic than the hemiplegia. Other migrainous symptoms such
as nausea, vomiting and photophobiamay be present. Hemiple-
gia may precede or accompany the headache. This variation is
often familial, dominantly inherited and linked to chromosome
19. A defect in the gene for the calcium channel is found in some
families. An increased risk of stroke exists in families with this
disorder. Diagnosis cannot be made during the ﬁrst attacks,
although it may be suspected in the presence of a positive family
history. Most serious causes of hemiplegic migraine, including
intracerebral haemorrhage,mass infection, or stroke need exclu-
sion. With repeated, stereotyped episodes and complete nor-
malcy between episodes, the diagnosis can be made with more
conﬁdence, particularly in the presence of a positive family
history. Differential diagnosis of repeated episodes includes
alternating hemiplegia of childhood, unobserved partial seizures
with postictal paralysis and mitochondrial cytopathies particu-
larly the mitochondrial encephalomyopathy, lactic acidosis and
stroke syndrome. Benign paroxysmal vertigo of childhood, thissyndrome presents with brief episodes of acute vertigo. Based on
the observation that a high proportion of children with benign
paroxysmal vertigo have a family history of migraine, this entity
is considered a migraine variant. This syndrome is not uncom-
mon andmost commonly leads to the development of more typ-
ical migraines later in childhood. Small children might ﬁnd it
difﬁcult to narrate the symptoms but typically cling to the parent
and look frightened. Headache does not follow the attack.
Opthalmoplegic migraine, this migraine variant may begin in
childhood. Acute disorders of eye movement, unilateral abnor-
mal papillary response or horner syndrome may precede or
accompany the headache. Migraine aura without headache,
Migrainous of any age may experience an aura with or without
the typical headache. In some, the headache may be minimal
while neurological symptoms predominate. Visual symptoms
without subsequent headache are fairly frequent. Differential
diagnosis includes occipital epilepsy, with or without an identi-
ﬁable lesion (Cuvellier et al., 2009).
1.3. Migraine variants in adults
Migraine with aura or classical migraine, is a form of headache,
which is severe, and usually one sided, frequently associated
with nausea and vomiting. This is usually followed by warning
symptoms, which usually affect the eyesight and are termed as
an Aura (Parsekyan, 2000). Migraine without aura or common
migraine has no classic warning signs, the patient may experi-
ence one or more symptoms several hours before headache
actually starts including feeling of elation or intense energy
craving for sweets, thirst, drowsiness, irritability or depression.
Retinal or ophthalmic migraine is repeated attacks of monocu-
lar scotoma or blindness lasting less than one hour and associ-
ated with headache. This condition may be broadly deﬁned as
transient or permanent monocular visual disturbances accom-
panying a migraine attack or occurring in an individual with
a strong history of migrainous episodes (Fasmer et al., 2011).
One may consider two forms of anterior visual pathway mi-
graine which include transient monocular blindness and perma-
nent unilateral visual loss which is quite uncommon. Basilar
migraine is a subtype of migraine with aura. Basilar artery mi-
graine presents itself with two or more of the following symp-
toms. They are visual symptoms like double vision and
dysarthria, ataxia, vertigo, tinnitus, bilateral parenthesis, de-
creased hearing, decreased level of consciousness and bilateral
paresis. Familial Hemiplegic Migraine, an autosomal dominant
characterized by attacks of transient hemi paresis followed by a
migraine headache, is divided into pure familial hemiplegic mi-
graine affecting 80% of families and familial hemiplegic mi-
graine with premature cerebellar signs affecting 20% of
families. Familial Hemiplegic Migraine (FHM) is a type of mi-
graine with aura. Complicated migraine is a type of migraine in
which migraine attacks are accompanied by permanent neuro-
logical deﬁcits, such as paralysis. Menstrual migraine, it is
thought to affect 15–20% of women population and according
to the American Academy of Neurotology, an estimated 50%
of these women experience migraine due to hormonal changes
that take place during their menstrual cycle. Menstrual
migraines are generally of longer duration and seen more in
debilitating persons. It is more likely to recur and is more resis-
tant to treatment than any other migraine. Abdominal Mi-
graine, it is an idiopathic disorder seen mainly in children but
quite uncommon in adults (d’Onofrio et al.,2006). It is also
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episodes of midline abdominal pain with attacks lasting 1–72 h.
The pain is of moderate to severe intensity and is felt in the mid-
line of the abdomen, usually around the umbilicus, or poorly
localized. The attacks of pain are usually accompanied by anor-
exia and nausea and half of the patients will vomit with at least
some attacks although some patient may appear ﬂushed. Post
hypoglycaemic migraine, it may occur exceptionally in patients
with unstable diabetes as a rebound phenomenon caused by an
unidentiﬁed mechanism. There is an increased prevalence of
headache in persons with diabetes. Although hypoglycaemic
may precipitate headache in some diabetic patients (Dowson
et al., 2004).1.4. Chronic headache disorders
Chronic migraineurs experience headaches more than half of
the days of month that ﬁt the criteria of migraine. The patients
will normally experience nausea and vomiting, sensitivity to
light, sound, or smells, with the pain experienced as throbbing
in nature and often on one side of the head. Even minor activ-
ity or simply bending forward can aggravate the pain and dis-
comfort. Usually sufferers from chronic headache disorders
abide much of the burden that they do not carry it all. This
is due to headache disorders which are most niggling in the
productive years, estimates of their ﬁnancial cost to society,
mainly from lost working hours and reduced productivity
are immense. For example, in UK, some 25 million working
or school days are lost every year because of migraine itself.
Tension type headache (TTH) is more common but less dis-
abling, while chronic daily headache (CDH) is less common
but more disabling, together cause losses which are almost cer-
tainly of at least similar magnitude. Chronic daily headache
(CDH) is a descriptive term that comprises several different
headache diagnoses (Rozen, 2003). Chronic daily headache af-
fects 4% of the adult population in the US and around the
globe (Castillo et al., 1999) while chronic TTH affects 1–3%
of adults. Chronic Headache ought to be a public health con-
cern. Even though there is good evidence that huge numbers of
people upset by headache do not receive actual care. Usually
chronic TTH originates during the teenage years and reaches
top levels in the 30’s (Guitera et al., 2002). Episodic TTH is
the most common headache disorder, reported by over 70%
of some populations. Its prevalence varies greatly. African
community-based studies have reported only 1.7% of the pop-
ulation affected, but cultural attitudes to reporting a relatively
minor complaint may largely explain this ﬁnding.2. Management
The various of treatment for children and adolescents with mi-
graines includes treatment modalities for acute attacks, pro-
phylactic medications when the frequency of attacks are
more, and biobehavioural modes of therapy for long-term
management of the disorder (Victor and Ryan, 2003).Treat-
ment methods for acute migraine attacks include tri-cyclic
antidepressants, ergot preparations, over-the-counter nonste-
roidal anti-inﬂammatory drugs (NSAIDs), as well as the oral
triptans such as sumatriptan succinate, rizatriptan benzoate,
zolmitriptan and the nasal spray formulations of sumatriptan
and zolmitriptan. Subcutaneous sumatriptan and parenteraldihydroergotamine have also been used limitedly (Papetti et
al., 2010). As prophylactic treatment for patients with frequent
or disabling migraines or both includes the antidepressants
amitriptyline hydrochloride and nortriptyline hydrochloride,
the anticonvulsants divalproex sodium and topiramate, and
the antihistaminic agent cyproheptadine hydrochloride. Bio-
behavioural approaches focused at addressing the fundamental
lifestyle issues and nonpharmacologic approaches to treatment
are fundamental to long-term success (Diener and Limmroth,
2001).
2.1. Nonpharmacologic methods
The effective management of this disorder often remains a
challenge. The predisposing factors that trigger migraine at-
tacks in susceptible individuals, remain unknown. Tradition-
ally, acute treatment and nonpharmacological treatment such
as behavioural and lifestyle changes including trigger avoid-
ance, prevention, assurance, and patient follow-up have all
been essential elements of migraine management. The use of
drugs known to cause headaches, which include reserpine,
indomethacin, nifedipine, theophylline derivatives, caffeine,
vasodilators including the long-acting nitrates, and alcohol,
should be stopped or substituted with other agents if possible.
The estrogens and oral contraceptives used should be discon-
tinued if they are suspected of contributing to the headaches,
although in some patients it is unavoidable (Niederberger
and Kropp, 2004). Exercise programs to promote well-being,
controlling the diet excesses, and avoiding prolonged fasts
and irregular sleeping habits can be helpful.
The matter of dietary factors in migraine is difﬁcult. Funda-
mental alterations in the diet are rarely justiﬁed and seldom
effective. Avoiding foods constituting nitrites, such as hot dogs
and preserved cold cuts, and of prepared foods containing
monosodium glutamate can be helpful. Avoiding monosodium
glutamate can be difﬁcult as it is the main constituent of many
canned and prepared foods and is widely used in restaurants,
especially in the preparation of Chinese dishes. The other food
products suspected of precipitating headache include ripened
cheeses, fermented food items, red wine, chocolate, chicken li-
ver and pork. These foods mostly contain tyramine, phenyleth-
ylamine, and octopamine. An occasional patient identiﬁes an
offending foodstuff, but in our experience, dietary precipita-
tion of migraine is uncommon. In some cases of migraine, at-
tacks are precipitated by strong odors, especially of the
perfume or aromatic type. Avoiding the use of strong-smelling
soaps, shampoos, perfumes, and other substances can be help-
ful for some individuals up to an extent. Everyone is undergo-
ing stress at one or in another way at daily life as a part of
work. People with migraine may note that stress is a triggering
factor for migraine attacks. Helping the patient compact with
or avoid stress is difﬁcult task. Stress management on long
term basis may require the help of a psychologist or other tech-
nically trained professional persons. Many techniques are used
including biofeedback, relaxation methods and hypnosis. Bio-
feedback, relaxation training, and cognitive behavioural train-
ing are found to be useful (Baumann, 2002).
2.2. Pharmacological management
Drug therapy can be administered prophylactically to prevent
episodes of migraine or symptomatically to relieve the pain,
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comes necessary when the frequency or duration of attacks
or the anxiety of attacks seriously interferes with the patient’s
lifestyle. Other indications for prophylaxis include the occur-
rence of severe or prolonged neurological symptoms or a lack
of response to symptomatic treatment. Generally a prophylac-
tic treatment should be considered if attacks occur as often as
one to two days per week (Schuurmans and van Weel, 2005).
2.3. Prophylactic treatment
The main drugs given for childhood migraine prophylaxis in-
clude betablockers like propranolol and metoprolol, ﬂunarizine
and valproic acid, tricyclic antidepressants like amitriptyline
hydrochloride and nortriptyline hydrochloride, Cyprohepta-
dine, and antihistamine with antiserotonergic but less useful in
teenagers, NSAIDs such as naproxen sodium and ibuprofen.
In this ﬂunarizine is the drug of ﬁrst choice. The most effective
prophylactic agents for adults include b-adrenergic blockers
propranolol, timolol, nadolol, atenolol, and metoprolol proba-
bly have approximately the same beneﬁt inmigraine as propran-
olol (Sonal et al., 2009). The only pharmacological trait that
separates b-adrenergic blocking agents effective in migraine
from those that are not is a lack of sympathomimetic activity.
Propranolol is more effective in patients with a single migraine
type, whereas amitriptyline is more beneﬁcial for patients
with mixed migraine and tension features (Meyer, 2009).
Amitriptyline also is useful in patientswith co-morbid insomnia.
Attacks of migraines during menses can be prevented with a
course of an NSAID beginning several days before menstrua-
tion and continuing during the ﬁrst few days of the period.NSA-
IDs can be especially helpful in patients with co-morbid
osteoarthritis. However, chronic NSAID use must be under-
taken cautiously because of the potential for adverse effects
involving the gastrointestinal tract and renal function (Mannix,
2004). Monoamine oxidase inhibitor (MAOI) phenelzine can
also be used. Unfortunately, the dietary restrictions that must
be carefully followed if a hypertensive crisis is to be avoided is
limiting the widespread use of these inhibitors for prevention
of migraine. For patients with particularly severe and intracta-
ble attacks, the MAOIs may be considered. Calcium-channel
blockers verapamil and ﬂunarizine have beneﬁt for preventing
recurrent attacks of migraine. Antiepileptic medications are
very effective in preventing migraine attacks. Divalproex so-
dium is an effective migraine preventive for adults but, it should
be avoidable for womenwho are at risk of becoming pregnant as
it is associated with an increased risk for neural tube defects.
Topiramate is the most recent addition to the antimigraine
armamentarium (Cruz et al., 2009). It is currently being investi-
gated as a migraine preventive agent in children and adolescents
(Loder and Biondi, 2005). Dosages for migraine prevention
range from 50 to 200 mg/d in single or divided doses. Serotoner-
gic Agent Methysergide is a derivative of lysergic acid diethyl-
amide it should be reserved for the most intractable migraine
and should be given for periods of only six months at a time. Be-
tween courses, methysergide should be discontinued for four
weeks. Cyproheptadine is also a peripheral serotonin antagonist
but only has less effect in adults. Others include riboﬂavin
administered orally in a dose of 400 mg/day and Botulinum tox-
inA injection (Sonal et al., 2009).2.4. Symptomatic treatment
The symptomatic treatment of migraine involves pharmaco-
logic and nonpharmacologic methods. Treatment includes
starting counselling as soon as clinical manifestations occur.
Apart from this use simple and appropriate dug in adequate
doses, management of dehydrations, sleep deprivation, nausea
and vomiting. Usually pharmacologic modalities include single
analgesics, combination analgesics with or without opiate nar-
cotics, nonsteroidal anti-inﬂammatory drugs (NSAIDs), ergot-
amine derivatives, and 5-HT1 receptor agonists. Patients
should be informed about continuous use of symptomatic
treatments which can lead to rebound headaches and eventu-
ally to chronic daily headaches (Hershey, 2010). Symptomatic
treatment should generally begin as early in the starting of an
episode as possible. Patients should take the medications if
aura is present and should not wait for the pain to begin.
Exception for this is sumatriptan in subcutaneous formulation,
which is less effective if administered earlier than the onset of
the headache phase. Presently sumatriptan and related selec-
tive serotonin receptor agonists are the treatment of choice
for chronic migraine episodes. For migraineurs with typical
migraines, mid-line treatment, Triptans are a suitable. But,
they may not effective for atypical or severe migraines, trans-
formed migraines, or status migraines. Generally Triptans
are highly effective in reducing the symptoms or aborting the
attack within 30–90 minutes in 70–80% of patients. Unusually
many patients have a recurrent migraine later in the day and
only one such recurrence in a day can be managed with a sec-
ond dose of a triptan. Triptans are now available as various
dosage forms like tablets (sumatriptan, zolmitriptan, rizatrip-
tan, almotriptan malate, eletriptan hydrobromide, naratriptan
hydrochloride, and frovatriptan succinate), dissolving tablets
(zolmitriptan and rizatriptan), injections (sumatriptan) and na-
sal sprays (sumatriptan and zolmitriptan). In young migrai-
neurs, triptans can be successfully used with increasing
frequency as rescue medications.
Availability of the various classes of medications and for-
mulations allows for ﬂexibility in the management plan. It
must be elicited, though that once the attack is fully developed.
Due to decreased gastrointestinal motility and poor absorp-
tion, usually oral preparations are less effective. More over if
vomiting starts, oral preparations are no longer useful. Till
the introduction of sumatriptan in 1985, ergot derivatives were
the main oral drugs available to manage a migraine once it is
established. The main role of ergot drugs are as a preventive or
abortive therapy. However, their relative higher expense and
cumulative side effects suggest reserving them as an abortive
rescue medicine. Ergotamine tartarate tablets, usually along
with caffeine, though highly effective, and long lasting (unlike
triptans), have fallen out of favour due to the problem of tem-
porarily disabling calf pain caused by overuse called ergotism.
Unless the patient is nauseated, oral ergotamine tablet absorp-
tion is reliable. For evening-night migraines, pure ergotamine
tartrate is highly effective. Dihydroergotamine (DHE), which
is available as injection or inhalation, can be as effective as
ergotamine tartrate, but is much more expensive. Intravenous
dihydroergotamine (DHE) is an effective abortive agent when
used early in an attack and is an option for the older child.
Children and adolescents often respond to over-the-counter
6 M. Sonal Sekhar et al.medication, including nonsteroidal anti-inﬂammatory drugs
(NSAIDs) or combination analgesics. Analgesics like Acetami-
nophen and Ibuprofen are safe, effective and widely used for
treatment of acute attacks of migraine in children. Some times
stronger analgesic medication such as butalbital may be neces-
sary. Because of the risk of Reye’s syndrome, Aspirin-contain-
ing compounds are of concern in children younger than
15 years. Although a combination of aspirin, caffeine, and
acetaminophen is effective in adult acute migraine, it has not
been tested in children for mild to moderate migraines. Even
other NSAIDs are effective if taken at a high but appropriate
dosage during the aura or early headache phase. In most mi-
graine patients occurs gastric stasis which causes delay in
absorption of oral medications. Sometimes, carbonated bever-
ages may improve absorption (Lewis, 2010).
Opiate analgesics like codeine, morphine or others agents
provide variable relief, but their side effects, chances of re-
bound headaches or overuse headache, and the risk of addic-
tion contraindicates their usual usage. Some of the dopamine
antagonists including prochlorperazine maleate and metoclo-
pramide hydrochloride were effective for the nausea and vom-
iting due migraine headaches. The earlier these drugs are used
in the management, the better their effect. Intravenous chlor-
promazine has proven very effective in treating status migrain-
ous which is a life-threatening condition. Uncomplicated, non-
nauseated cases can be treated with 20 mg of prednisone tab-
lets every eight hours until the migraine stops, followed by
mandatory tapering off the doses. Compared to ketorolac,
prochlorperazine is more effective in the reduction of symp-
toms in one hour after intake in controlling severe acute mi-
graine attack in the emergency department (Mack, 2010).3. Conclusion
Childhood and adult migraine are common public problems
among the primary complaints of the both populations. These
two exhibit slightly different from each other, but not enough
to categorize either as unique. The reason for this is migraine
research still has to go a long way, because researchers have
done only few studies that are comprised of large sample sizes,
or that can comprehensively separate psychosocial and physi-
ological inﬂuences as well as therapies. Moreover, it is not yet
clear whether genetic factors or socio-psychological parame-
ters exert more inﬂuence over the other factors in determining
the speciﬁc etiopathogenesis of migraine. But migraine in gen-
eral is presumed to be due to a genetic predisposition with
environmental and systemic triggers. For the general practitio-
ners there is little known about clinical features and treatment
strategies. Generally headache practitioners consider the age
related differences of headache characteristics and manage-
ment schedules.
Doing a speciﬁc diagnosis that attacks are migrainous in
origin may be quite helpful in their management. Usually
families are relieved to know that the child does not have a
more serious condition like brain tumour and that further un-
wanted medical intervention may not be necessary. If episodes
present on multiple occasions, with complete resolution
between episodes, particularly in the evidence of a positive
family history of migraine, extensive laboratory testing and
imaging can be avoided. During the ﬁrst episode, if the childis observed acutely, more extensive evaluation may be neces-
sary to exclude alternative diagnoses.
Various studies have reported prevalence rates of migraine
in paediatric population have increased worldwide. The higher
prevalence rates reported in the Scandinavian and other stud-
ies may be due to the use of different diagnostic criteria. De-
spite its prevalence, migraine remains generally under
diagnosed or misdiagnosed, just as in adults in whom migraine
is often attributed to sinus disease. The misdiagnosis has been
demonstrated in adults to result in a signiﬁcant impact on
treatment, disability, and quality of life. Correspondingly in
children, frequent headaches can cause a signiﬁcant impact
on disability and quality of life, prompting the need for early
identiﬁcation and treatment. The long-term outcome of child-
hood headaches and evolution into adult headaches remains
largely unknown. It has been suggested that for adults mi-
graine may represent a progressive disorder. In children, how-
ever, the progressive nature is uncertain and further
investigations into longitudinal outcome and phenotypic
changes in childhood headaches have yet to be recognized.
Most of the therapeutic agents are developed from research
data extrapolated from adult interventional studies with con-
cerns of safety and efﬁcacy when using these agents in children.
Current focus in management of recurrent headaches in adults
involves nonpharmacological modalities like dietary modiﬁca-
tion and stress management. Application of these possibilities
especially permits further explaining in respect to its relevance
in paediatric migraine management.
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